Regulation of Phosducin-like Protein by Casein Kinase 2 and N-terminal Splicing*

Jan Humrich, Christina Bermel, Tobias Grübel, Ursula Quitterer, and Martin J. LohseDagger

From the Institute of Pharmacology and Toxicology, University of Würzburg, Versbacher Strasse 9, 97078 Würzburg, Germany

Received for publication, June 26, 2002, and in revised form, November 11, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Phosducin-like protein (PhLP) is a member of the phosducin family of G-protein beta gamma -regulators and exists in two splice variants. The long isoform PhLPL and the short isoform PhLPS differ by the presence or absence of an 83-amino acid N terminus. In isolated biochemical assay systems, PhLPL is the more potent Gbeta gamma -inhibitor, whereas the functional role of PhLPS is still unclear. We now report that in intact HEK 293 cells, PhLPS inhibited Gbeta gamma -induced inositol phosphate generation with ~20-fold greater potency than PhLPL. Radiolabeling of transfected HEK 293 cells with [32P] revealed that PhLPL is constitutively phosphorylated, whereas PhLPS is not. Because PhLPL has several consensus sites for the constitutively active kinase casein kinase 2 (CK2) in its N terminus, we tested the phosphorylation of the recombinant proteins by either HEK cell cytosol in the presence or absence of kinase inhibitors or by purified CK2. PhLPL was a good CK2 substrate, whereas PhLPS and phosducin were not. Progressive truncation and serine/threonine to alanine mutations of the PhLPL N terminus identified a serine/threonine cluster (Ser-18/Thr-19/Ser-20) within a small N-terminal region of PhLPL (amino acids 5-28) as the site in which PhLPL function was modified in HEK 293 cells. In native tissue, PhLPL also seems to be regulated by phosphorylation because phosphorylated and non-phosphorylated forms of PhLPL were detected in mouse brain and adrenal gland. Moreover, the alternatively spliced isoform PhLPS was also found in adrenal tissue. Therefore, the physiological control of G-protein regulation by PhLP seems to involve phosphorylation by CK2 and alternative splicing of the regulator.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Phosducin-like protein (PhLP)1 was initially cloned as a product of an ethanol-responsive gene in NG108-15 neuroblastoma x-glioma cells (1). PhLP has a high sequence homology to the G-protein beta gamma -subunit (Gbeta gamma ) regulator phosducin. Similarly, as phosducin, PhLP has been found to bind to Gbeta gamma with high affinity (2) and act as a Gbeta gamma -binding protein in intact cells (3). The PhLP mRNA exists in two major splice variants coding for two proteins, which differ by the presence (PhLPL) or absence (PhLPS) of the N-terminal 83 amino acids (1, 4). Subsequent studies on diverse tissues demonstrated that PhLPL is expressed in many organs at high protein levels (e.g. brain, heart, and liver), whereas PhLPS protein levels could not or only hardly be detected in these organs (4, 5). Direct comparison of the affinities toward Gbeta gamma showed a 15-fold weaker interaction for PhLPS compared with phosducin or PhLPL (5). Therefore, PhLPS had been believed to play only a minor role in G-protein regulation. Recently, it was reported that PhLPS could be purified from cultured bovine chromaffin cells where it might inhibit nicotine-stimulated exocytosis of catecholamines by a pathway involving a Gbeta gamma ·ADP-ribosylation factor 6 complex (6). These findings suggested that alternative splicing of PhLP might indeed occur in at least one organ or under specific conditions and therefore might play a role in differential functions of the PhLP isoforms.

Regulation of the homologous protein phosducin has been found to occur by phosphorylation via the serine/threonine kinases PKA, GRK, or CaM-dependent kinase II (7-11). Phosphorylation of phosducin reduces the affinity for Gbeta gamma , and as a consequence, phosducin looses its ability to regulate G-protein function. In the case of PhLP, phosphorylation as a regulatory mechanism has been suggested but has never been demonstrated (10). Here we report that the Gbeta gamma -regulatory function of PhLPL is inhibited in cells by N-terminal phosphorylation via casein kinase 2 (CK2), whereas PhLPS lacks such a regulatory mechanism. CK2 is a constitutively active and ubiquitously expressed serine-threonine kinase (12, 13). Our findings further provide strong evidence that the extended N terminus of PhLPL becomes autoinhibitory upon phosphorylation by CK2. In contrast, alternative splicing leads to PhLPS, which is not a substrate for CK2 and thus escapes this inhibitory mechanism.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- [32P]ATP, [32P]orthophosphoric acid, and myo-[2-3H]inositol were purchased from PerkinElmer Life Sciences. The kinase inhibitors staurosporine, BAPTA-AM, and 5,6-dichloro-1-beta -D-ribofuranylbenzimidazole (DRB) were purchased from Calbiochem. Heparin sodium salt (average molecular weight 6,000) was from Sigma. Primary antibodies used were rabbit polyclonal anti-PhLPS as described previously (5) and rabbit polyclonal anti-PhLP-CT. This synthetic peptide was derived from the very C terminus of PhLPL and PhLPS (sequence: CHSEDSDLEID). After coupling to keyhole limpet hemocyanin (14, 15), antibodies were raised in rabbits with two boost injections and collected as serum. Secondary goat anti-rabbit-horseradish peroxidase was from Dianova. Protein A-Sepharose was obtained from Amersham Biosciences. Phosphorimaging and quantification were done on a FLA-3000 from Fuji. ScanProsite was accessed at www.expasy.ch.

Construction of Expression Vectors-- All of the cDNAs used in these studies were subcloned into pcDNA3. The cDNA for PhLPL was originally cloned from rat brain (2). The construction of deletion mutants and Ser/Thr to Ala mutants of PhLPL were done by a PCR-based strategy and confirmed by automated sequencing.

Cell Culture, Transient Transfection, and Determination of Inositol Phosphates-- Human embryonic kidney (HEK) 293 cells were grown in DMEM, 10% fetal calf serum and were kept in 7% CO2 humidified atmosphere. Cells were transfected by using the CaPO4 method (16) on 10-cm dishes at 70% confluency with a constant total amount of DNA. Transfection efficiency was usually between 60 and 80% and was equal for all of the cDNAs used as controlled by transfection of different green fluorescent protein-tagged constructs. For determination of inositol phosphates, cells were seeded in six-well plates and labeled with myo-[2-3H]inositol (2 µCi/ml; specific activity 21 Ci/mmol) for 16 h in inositol-free RPMI 1640 medium containing 0.2% fetal calf serum. Unlabeled cells from the same transfection also seeded in six-well plates were used for Western blotting to control expression levels. After labeling, cells were washed once in incubation buffer (138 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.6 mM CaCl2, 1 g/liter glucose, 20 mM Na+-HEPES, pH 7.3) and then incubated at 37 °C for 20 min in incubation buffer containing 10 mM LiCl. Reactions were stopped, and inositol phosphates were extracted as described previously (17). Inositol determinations were performed in triplicates, and results were analyzed as the means ± S.E. of at least three independent experiments. ANOVA and post-test comparison (Bonferroni) were performed as appropriate. For the control of expression levels, cells of one well were lysed in 250 µl of hypotonic lysis buffer (1% Triton X-100, 20 mM Tris base, pH 10.5) for 15 min on ice and then centrifuged. Supernatants were analyzed by Western blots using polyvinylidene difluoride membranes (Millipore) and anti-PhLP-CT antibodies. Detection was performed with goat anti-rabbit-horseradish peroxidase antibodies and the Uptilight horseradish peroxidase-blotting kit (Interchim).

Phosphorylation of Phosducins-- Phosducin, PhLPL, and PhLPS were purified from Escherichia coli as C-terminally His6-tagged proteins (5). PKA phosphorylation was performed as described (10), and phosphoproteins were visualized by exposure to Biomax MS films (Eastman Kodak Co.). CK2 kinase assays were performed with recombinant human CK2 enzyme (Roche Molecular Biochemicals) or cell extracts. In kinase assays using recombinant human CK2, a 50-µl volume containing 400 nM recombinant PhLPL, PhLPS or phosducin, CK2 buffer (20 mM Tris-HCl, pH 7.5, 50 mM KCl, 10 mM MgCl, 5 mM dithiothreitol), 0.04 or 0.3 milliunit of CK2, and 200 µM ATP (1 µCi of [32P]ATP) was incubated at 30 °C for 30 min or at 37 °C for 120 min. The reaction was terminated by boiling samples in Laemmli buffer followed by SDS-PAGE, Coomassie Blue staining, and phosphorimaging. For kinase assays using HEK cell cytosol, a lysate was prepared by resuspending cells of one 15-cm dish in 5 ml of CK2 buffer (supplemented with 1 mM PMSF), disrupting the cells by sonication and clearing the lysate by centrifugation (20,000 × g, 10 min). Protein content was determined in the supernatant by the Bradford method. Phosphorylation was then performed by adding 150 µg of total protein of cell extract to a 250-µl reaction with 400 nM His6-tagged protein and 10 µCi of [32P]ATP and incubated at 30 °C for 30 min. Reactions were then placed on ice, diluted with 5 volumes of ice-cold pull-down buffer (20 mM Tris-HCl, pH 8.0, 500 mM NaCl), supplemented with 50 µl of Ni-NTA-agarose (Qiagen), and rotated at 4 °C for 10 min. The beads were then washed, boiled, and analyzed by SDS-PAGE and phosphorimaging. Phosphorylation of PhLP in intact HEK 293 cells was done essentially as described with minor modifications (18). 48 h after transfection and 36 h after seeding in six-well plates, HEK 293 cells were washed in phosphate- and serum-free DMEM supplemented with 20 mM Na+-HEPES, pH 7.4, (labeling buffer) and then incubated in the same buffer for 30 min. Labeling of the intracellular ATP pool was then performed with 200 µCi/ml [32P]orthophosphoric acid (specific activity 10 mCi/ml) for 2 h at 30 °C. Where indicated, cells were stimulated with 1 mM carbachol for 5 min. Cells were immediately placed on ice and washed once with ice-cold buffer. The cells then were lysed on ice with 1 ml of lysis buffer (300 mM NaCl, 50 mM NaF, 5 mM Na4P2O7, 5 mM EDTA-Na2, 0.1 mM Na3VO4, 1% Triton X-100, 0.01% NaN3, 50 mM Tris-HCl, pH 7.2, freshly supplemented with 10 mM iodoacetamide and 1 mM PMSF). After 20 min, the Triton X-100-insoluble fractions were removed by centrifugation (20,000 × g for 15 min) and PhLP was immunoprecipitated from the supernatants by the anti-PhLPS antibody precoupled to protein A-Sepharose for 2 h at 4 °C. After washing, immunoprecipitates were subjected to SDS-PAGE, and radiolabeled PhLP was visualized and quantified by phosphorimaging. Expression of PhLP was controlled by Western blotting of an aliquot obtained from the centrifuged lysates (with the use of the anti-PhLP-CT antibody).

Tissue Preparation and Dephosphorylation-- Mouse heart, brain, adrenal gland, and embryo (day 10.5 post-conception) were homogenized in five volumes of the same lysis buffer as described above (containing phosphatase inhibitors). After centrifugation and adjustment of total protein levels in supernatants as indicated, samples were subjected to SDS-PAGE and Western blotting. In the case of dephosphorylation experiments, lysis was performed in 40 mM Tris base, pH 10.5, 1% Triton X-100, and 1 mM PMSF (phosphatase inhibitors were omitted), samples were cleared by centrifugation (20,000 × g for 10 min), and protein content was determined by the Bradford method. Dephosporylation was then performed by adding 50 µg of HEK cell lysate or 100 µg of brain lysate to a 50-µl reaction with phosphatase buffer (50 mM Tris-HCl, pH 7.5, 2 mM MnCl2, 0.1 mM EDTA, 5 mM dithiothreitol, 0.01% Brij 35) and with or without 1000 units of lambda -protein phosphatase (lambda -PPase) (New England Biolabs) at 37 °C for 20 min. The reaction was terminated by boiling in Laemmli buffer followed by SDS-PAGE and Western blotting.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Inhibition of Inositol Phosphate Signaling in Intact HEK 293 Cells-- To investigate the functional role of PhLPL and PhLPS as Gbeta gamma -regulators in living cells, we subcloned the appropriate cDNAs into the pcDNA3 expression vector and determined the inositol phosphate formation stimulated by the transient co-transfection of phospholipase Cbeta 2 (PLCbeta 2) and G-protein subunits Gbeta 1 and Ggamma 2 as described previously (19, 20). Without addition of any Gbeta gamma -inhibiting proteins, the transfection of PLCbeta 2 and Gbeta 1gamma 2 cDNA (3 µg each) enhanced basal inositol phosphate accumulation ~5-fold compared with mock-transfected cells (data not shown). Co-transfection of the cDNA encoding PhLPL inhibited the Gbeta gamma -stimulated production of inositol phosphates significantly (Fig. 1A). Unexpectedly, the short splice variant PhLPS turned out to be more effective than the long splice variant PhLPL, although PhLPS interacts with purified Gbeta gamma less efficiently than PhLPL (5). Co-transfection of 8 µg of cDNA for each Gbeta gamma -binding protein inhibited the total inositol phosphate formation by 32.2 ± 8.4% (n = 13) for PhLPL, 78.3 ± 3.8% (n = 7) for PhLPS, and 75.0 ± 4.0% (n = 3) for GRK2-K220R, which served as positive control (21). Because inositol phosphate levels of untransfected control cells were ~20% of the inositol phosphate levels of PLCbeta 2, Gbeta 1gamma 2 co-expressing cells (data not shown), inhibition by ~80%, can be considered full inhibition. Thus, inhibition by PhLPS was almost complete. The differences between control and PhLPL and between PhLPL and PhLPS were highly significant (p < 0.01). The different effects of PhLPL and PhLPS were not because of different protein expression as shown by Western blot analysis of the transfected cells (Fig. 1B). The blot with samples from three independent experiments shows equal expression of PhLPL and PhLPS within individual experiments and between different experiments.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 1.   Inhibition of Gbeta gamma -stimulated inositol phosphate generation in HEK 293 cells. A, HEK 293 cells were transiently transfected with 8 µg of cDNA of PhLPL, PhLPS, GRK2-K220R, or empty vector (control) and with 3 µg of cDNA of Gbeta 1, Ggamma 2, and PLCbeta 2/10-cm dish. Inositol phosphate levels were determined 42 h later as described under "Experimental Procedures." (***, p < 0.001; **, p < 0.01 versus control; ##, p < 0.01; and #, p < 0.05 versus PhLPL). B, Western blot of three independent experiments comparing protein expression levels of PhLPL and PhLPS after transfection. Gels were loaded each with 20% of the cell lysate from one well of a 6-well plate, and detection was done with the polyclonal PhLP-CT antibody as described under "Experimental Procedures."

To analyze further the different effects of PhLPL and PhLPS on Gbeta gamma -function, dose-response experiments were performed. The cDNA of PhLPL or PhLPS was diluted with empty vector to maintain the total amount of transfected cDNA, and inositol phosphates were determined as before. As shown in Fig. 2A, the IC50 of PhLPL was 20-fold higher than that of PhLPS (13.2 and 0.64 µg of cDNA, respectively). Fig. 2, B and C, shows that the transfection of HEK 293 cells with increasing amounts of cDNA did indeed result in the expression of corresponding amounts of PhLPL or PhLPS, respectively.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 2.   Concentration-dependent effects of PhLPL and PhLPS on inositol phosphate generation. A, HEK 293 cells were transiently transfected with various amounts of cDNA for PhLPL or PhLPS. The IC50 of PhLPL was 20-fold higher than that of PhLPS (13.2 and 0.64 µg cDNA/10-cm dish, respectively). B and C, Western blots demonstrating increasing protein levels of PhLPL (B) and PhLPS (C) under the same conditions as in panel A. Note that different exposure times of the films were used to cover the full range of protein expression. The polyclonal PhLP-CT antibody was used as described under "Experimental Procedures."

Phosphorylation of PhLPL and PhLPS in HEK 293 Cells-- To analyze the role of phosphorylation in intact cells as a possible regulatory mechanism, we labeled HEK 293 cells with [32P]orthophosphate and looked for basal- and receptor-stimulated phosphorylation. PhLP cDNAs were co-transfected with M3 muscarinic receptor cDNA. The M3 muscarinic receptor was chosen because of the prominent inositol phosphate signal that can be achieved by its stimulation (data not shown). 48 h after transfection, the receptors were stimulated with carbachol for 5 min (Fig. 3). PhLPL exhibited a markedly higher degree of basal phosphorylation compared with PhLPS. However, in both cases, stimulation of the M3 receptor by carbachol did not enhance the extent of phosphorylation (Fig. 3A, left panel). Fig. 3B summarizes a series of similar experiments demonstrating that the basal phosphorylation of PhLPL was ~8-fold higher than that of PhLPS, but that carbachol did not significantly stimulate the phosphorylation of PhLPL or of PhLPS. Expression was controlled by Western blotting with the PhLP-CT antibody and showed that both proteins were equally expressed (Fig. 3A, right panel). Overexpression of PhLPS did not affect the phosphorylation state of PhLPL (data not shown). These findings demonstrate that PhLPL was constitutively phosphorylated in HEK 293 cells, whereas PhLPS only exhibited very low levels of phosphorylation.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 3.   PhLPL phosphorylation is constitutive and M3 muscarinic receptor-independent in HEK 293 cells. HEK 293 cells transiently transfected with M3 muscarinic receptor (2 µg) and PhLPL or PhLPS cDNA (8 µg) were labeled with [32P]orthophosphate, stimulated with carbachol (1 mM), and processed as described under "Experimental Procedures." A, shown are 32P-labeled proteins as visualized by phosphorimaging (32P) and the expression control as performed by immunoblot (IB:PhLP-CT) of one of three independent experiment with similar results. There is marked basal phosphorylation in PhLPL, whereas in PhLPS, phosphorylation is only low in HEK 293 cells. Expression levels of both constructs were comparable. B, shown is the 32P incorporation in PhLPL and PhLPS with and without M3 muscarinic receptor stimulation by carbachol (means ± S.E.) of three to five independent experiments as the fold of basal PhLPL phosphorylation. Stimulation of PhLPL or PhLPS phosphorylation by carbachol treatment did not result in a significant increase. However, there was a 8-fold difference in the phosphorylation between basal PhLPL and basal PhLPS (***, p < 0.001). Data were determined by phosphorimaging as described under "Experimental Procedures."

Identification of CK2 as the Kinase Responsible for PhLPL Phosphorylation in HEK 293 Cells-- To identify the responsible kinase for PhLPL phosphorylation, a computer analysis (ScanProsite) of the sequence of the N-terminal 83 amino acids of PhLPL revealed seven putative CK2 phosphorylation sites each within a classical CK2 phosphorylation motif ((S/T)-X-X-(D/E)) (see (Fig. 5A)). To test whether PhLPL could be a substrate of CK2 phosphorylation in vitro, we performed kinase assays with human recombinant CK2 and found that recombinant PhLPL was indeed a substrate, whereas PhLPS and phosducin were not (Fig. 4A). We used the potent but unspecific kinase inhibitor staurosporine (22) and the intracellular Ca2+ chelator BAPTA-AM (23, 24) to test their effects on recombinant CK2 and found no effect on PhLPL phosphorylation. On the other hand, we tested two substances that were known to inhibit CK2: the glycosaminoglycan heparin (EC50 ~3 nM) (12, 25) and the nucleoside derivative DRB (EC50 ~7 µM) (26, 27). In the in vitro kinase assay, 3 µM heparin completely abolished PhLPL phosphorylation by CK2 and 100 µM DRB markedly inhibited PhLPL phosphorylation. To determine whether CK2 is the predominant PhLPL kinase in HEK 293 cells, we performed kinase assays using HEK cell lysate and recombinant PhLPL with and without the addition of kinase inhibitors and recombinant PhLPS as well as phosducin (Fig. 4B). Previous studies have shown that CK2 is abundantly present in mammalian cell lysates (12, 28). Here we demonstrate that PhLPL but not PhLPS or phosducin was predominantly phosphorylated by HEK cell lysate. This phosphorylation was inhibited by heparin (3 µM) and DRB (100 µM), whereas staurosporine only weakly inhibited and BAPTA-AM weakly stimulated the phosphorylation of PhLPL. These results provide strong evidence that CK2 is the predominant kinase in HEK 293 cells that constitutively phosphorylates PhLPL. We then asked whether PhLP was also a substrate for PKA phosphorylation in vitro similar to PKA-dependent phosphorylation of the homologous protein phosducin. PKA kinase assays were done with the same concentration (400 nM) of purified recombinant phosducin, PhLPL, and PhLPS (Fig. 4C). Phosducin was an excellent PKA substrate, whereas both PhLP variants were not. They roughly showed 10-20-fold less radioactivity incorporated than phosducin. These results demonstrate that the different members of the phosducin family exhibit differential regulation by different kinases.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 4.   Phosphorylation of recombinant phosducin and PhLP by HEK cell lysate, recombinant casein kinase 2, and protein kinase A. Equimolar concentrations (400 nM) of recombinant C-terminally His6-tagged PhLPL (14.04 µg/ml), PhLPS (10.3 µg/ml), and phosducin (11.62 µg/ml) purified from E. coli were phosphorylated by either recombinant human casein kinase 2 or by HEK cell lysate or purified catalytic subunit of PKA. A, recombinant human CK2 (0.04 milliunit/reaction) was used to phosphorylate recombinant PhLPL, PhLPS, and phosducin at 30 °C for 30 min. After SDS-PAGE and Coomassie Blue staining (Coomassie), the gel was subjected to phosphorimaging (32P). CK2 phosphorylated PhLPL efficiently, whereas PhLPS was only phosphorylated weakly (21% PhLPL) and phosducin was not (2% PhLPL). The concentration of the inhibitors used was 1 µM for staurosporine (Stauro), 100 µM for BAPTA-AM (BAPTA), 3 µM for heparin, and 100 µM for DRB. Me2SO (DMSO) (1% v/v) served as solvent control. B, HEK 293 cell lysate extracted as detailed under "Experimental Procedures" was used to phosphorylate recombinant PhLPL in the absence or presence of kinase inhibitors as well as PhLPS and phosducin at 30 °C for 30 min. Recombinant proteins were pulled down by Ni-NTA-agarose and processed as described under "Experimental Procedures." Control denotes HEK cell lysate without any recombinant protein and reflects background phosphorylation. Shown is the gel as visualized by phosphorimaging (32P) and by Coomassie Blue staining (Coomassie). PhLPL phosphorylation was inhibited by heparin and DRB (both known to inhibit CK2) but not by staurosporine or BAPTA, whereas PhLPS or phosducin was only weakly phosphorylated. C, recombinant phosducin, PhLPL, and PhLPS were phosphorylated by the catalytic subunit of PKA (100 units) at 30 °C for 15 min. Reactions were stopped by Laemmli buffer, boiled, and separated on 12.5% SDS-PAGE. Shown is the film (32P) and the corresponding gel (Coomassie) to demonstrate that PKA phosphorylation of PhLP isoforms is not significant compared with phosducin.

Identification of a Small Regulatory Region in the PhLPL N Terminus-- We then asked whether any particular region of the PhLPL N terminus was responsible for the weaker functional effects of PhLPL compared with PhLPS as well as for the constitutive phosphorylation in HEK 293 cells. As depicted in Fig. 5A, the N terminus of PhLPL contains several putative phosphorylation sites that occur in clusters of serines and threonines. Seven of these sites could serve as CK2 phosphorylation sites. We constructed PhLPL mutants by stepwise shortening of the N terminus. The five PhLPL constructs were as follows: L5 (amino acids 5-301 with the loss of Thr-2 and Thr-3), L29 (amino acids 29-301 with the additional loss of Ser-18, Thr-19, Ser-20 and Ser-25), L36 (amino acids 36-301), L46 (amino acids 46-301 with the additional loss of Ser-39, Ser-40, Ser-41, and Thr-42), and L58 (amino acids 58-301 with the additional loss of Ser-54 and Thr-57). The determination of Gbeta gamma -dependent inositol phosphate generation showed that a region within amino acids 5-28 caused the only major step in the gain of inhibitory function from PhLPL to PhLPS as demonstrated by the functional difference between L5 and L29 (Fig. 5A, lower panel). The removal of the first 28 amino acids of PhLPL (as in L29, L36, L46, and L58) was sufficient to gain the full Gbeta gamma -inhibitory activity of PhLPS. Western blots showed that all of the constructs with the exception of L5 were stable and that the expression levels of the constructs were comparable (Fig. 5B).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 5.   Progressive truncation of the PhLPL N terminus revealed a short regulatory region between amino acids 5 and 28. A, the extended N terminus of PhLPL contains several clusters of putative phosphorylation sites (S, serine; T, threonine) as depicted in the upper part of the panel. Arrows indicate the possible CK2 phosphorylation sites, whereas the numbers over the arrowheads indicate the amino acids C-terminal of the cutting point of the truncated constructs of PhLPL. The removal of the first 28 amino acids of PhLPL (L29, L29) was sufficient to gain the same Gbeta gamma -inhibitory effect as PhLPS, whereas removing the first four amino acids (L5) was not. Additional progressive truncation did not change this effect any further. The inhibition of the inositol phosphate signal was by 42 ± 11% (n = 5) for PhLPL, 52 ± 9% (n = 5) for L5, 84 ± 1% (n = 3) for L29, 85 ± 2% (n = 3) for L36, 84 ± 1% (n = 3) for L46, 85 ± 2% (n = 5) for L58, and 84 ± 3% (n = 5) for PhLPS (**, p < 0.01; ***, p < 0.001 versus PhLPL). B, expression control of the five N-terminally truncated constructs in comparison to that of PhLPL and PhLPS. Transfections were done as in inositol phosphate measurements, and 20% of the lysate of one well of a 6-well plate/lane was used. Shown is one of two Western blots with similar results. Used was the polyclonal PhLP-CT antibody as described under "Experimental Procedures."

Effect of Mutation of Serine 18, Threonine 19, and Serine 20 to Alanines-- We next asked whether the putative CK2 phosphorylation sites of the region compromising amino acids 5-28 might play a functional role in PhLPL regulation, and if so, which of the four candidates (Ser-18, Thr-19, Ser-20, and Ser-25) was involved. Two mutants were constructed, PhLPLA18-20 in which Ser-18, Thr-19, and Ser-20 were changed to alanines, and PhLPLA25 in which Ser-25 was changed to an alanine. These constructs were tested for their ability to inhibit Gbeta gamma -dependent inositol phosphate generation. PhLPLA18-20 showed the same Gbeta gamma -inhibitory capability as PhLPS and L29 (Fig. 6A), whereas PhLPLA25 exhibited the same functional capability as PhLPLA25. The differences between the effects of PhLPL and PhLPLA25 on the one hand and PhLPS, L29, and PhLPLA18-20 on the other hand were highly significant (Fig. 6A). Again, equal expression of the constructs was demonstrated in Western blot experiments (Fig. 6B). These data suggest that the cluster of Ser-18, Thr-19, and Ser-20 contains the phosphorylation sites responsible for the diminished Gbeta gamma -inhibitory effects of PhLPL, whereas Ser-25 most probably was not involved. Overexpression of PhLPL in a 4-fold excess over PhLPS or PhLPLA18-20 reduced the inhibition of the latter to the level exerted by PhLPL alone (Fig. 6C), suggesting that PhLPL competed with PhLPS for inhibiting Gbeta gamma . A 4-fold overexpression of PhLPL over PhLPS was controlled by Western blots (data not shown).


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 6.   Alanine mutation of Ser-18, Thr-19, and Ser-20 (PhLPL A18-20) but not of Ser-25 (PhLPL A25) was sufficient to yield full Gbeta gamma -inhibitory activity. A, HEK 293 cells were transiently transfected, and the inositol phosphate generation was determined as before (**, p < 0.01 versus PhLPL; #, p < 0.05 versus PhLPLA25 and p > 0.05 for PhLPL versus PhLPLA25). B, expression controls exhibit similar protein levels for all constructs as shown in one of three Western blots with similar results. Used was the PhLP-CT antibody as described under "Experimental Procedures." C, effects of co-expression of various forms of PhLP on inositol phosphate generation. The amount of PhLP cDNA transfected/10-cm dish is indicated, whereas total amount of cDNA was held constant with empty vector (***, p < 0.001 versus PhLPS; ##, p < 0.01 versus PhLPLA18-20 and p < 0.001 for all versus control).

In Vivo Relevance of PhLP Splicing and Phosphorylation-- Finally, we asked whether the observed phenomenon of PhLP regulation via N-terminal phosphorylation or splicing might play a role in different mouse organs, which had been described to contain considerable amounts of PhLPL (heart and brain) (4, 5) and which might also contain PhLPS (adrenal gland) (6). In addition, embryos were chosen because CK2 plays an essential role in developing cells and cell cycle progression (13). Therefore, we expected to detect a high level of phospho-PhLPL. PhLPL was detected by Western blotting in all three organs as well as in day 10.5 embryo and also in control (empty vector) transfected HEK 293 cells (Fig. 7A). In contrast, PhLPS was present in clearly detectable amounts only in the adrenal gland and in HEK 293 cells after transfection of the PhLPS cDNA (Fig. 7A). After longer exposure of the film, PhLPS seemed to be present also in heart and brain but not in HEK 293 cells or embryo (data not shown). In most instances, PhLPL ran as a doublet, one band corresponding to the position of recombinant PhLPL purified from E. coli (Fig. 7, A and B, lower arrowhead) and one to the position of cellular PhLPL (Fig. 7, A and B, upper arrowhead). Because the presence of phosphate moieties is known to change the gel mobility, we wondered whether the mutation in Ser-18, Thr-19, and Ser-20 (PhLPLA18-20) would lead to a similar gel mobility shift (Fig. 7B). Indeed PhLPLA18-20 corresponded to the lower band in brain and adrenal gland as well as recombinant PhLPL purified from E. coli (Fig. 7B). HEK 293 cell lysate and mouse brain lysate were then treated with lambda -PPase, which has been described to efficiently remove phosphates from serine, threonine, and tyrosine residues (29). This resulted in the loss of the PhLPL high molecular mass form as detected by Western blotting, whereas the low molecular mass form of PhLPL became detectable in HEK 293 cells and was enhanced in mouse brain (Fig. 7C). The contention that the upper band represents phosphorylated PhLPL was supported by the observation that phosphorylation of PhLPL by CK2 in vitro caused a reduction of gel mobility (Fig. 7D). Together, these data demonstrate that there is constitutive phosphorylation of PhLPL in different mouse tissues and that in brain and adrenal gland non-phosphorylated PhLPL seems to play a role.


View larger version (40K):
[in this window]
[in a new window]
 
Fig. 7.   Mouse tissue differentially expresses PhLPL and PhLPS and exhibits phosphorylated and non-phosphorylated PhLPL. A, Western blot analysis of recombinant PhLPL and PhLPS (0.1 pmol), 20 µg of total protein of cell lysates of control transfected, PhLPL- or PhLPS-transfected HEK 293 cells, and 200 µg of total protein of mouse heart, brain, adrenal gland, and embryo. Preparation of two different mice was performed in the presence of phosphatase inhibitors as detailed under "Experimental Procedures" and showed the same result. Adrenal gland has a prominent band of the size of PhLPS. Brain and adrenal gland show two bands: the upper one corresponding to the size of PhLPL in HEK 293 cells (transfected and endogenous) and the lower one corresponding to the size of PhLPL purified from E. coli. The PhLPS antibody has considerable cross-reactivity to the endogenous phosducin, which has an apparent gel size of 33 kDa. B, close-up view of a Western blot of 100 µg of total protein of mouse tissue (brain, adrenal gland, and embryo), 10 µg of total protein of HEK 293 cell lysate (PhLPL and PhLPL A18-20), and PhLPL (0.1 pmol) purified from E. coli. In brain and adrenal gland, doublets are detectable, whereas in embryo, only a single band is visible. Mutation of the phosphorylation sites Ser-18, Thr-19, and Ser-20 to Ala caused a shift in mobility of PhLPL in SDS-PAGE from that of wild-type PhLPL-transfected HEK 293 cells to that of unphosphorylated recombinant (rec.) PhLPL and corresponded to the size of the lower band in mouse brain and adrenal gland. C, HEK cell lysate (50 µg of total protein) and mouse brain lysate (100 µg of total protein) were prepared as described under "Experimental Procedures" and subjected to dephosphorylation by 1000 units of lambda -PPase at 37 °C for 20 min. Controls were incubated without the phosphatase. In native probes, PhLPL could be dephosphorylated by lambda -PPase and changed its gel mobility in a 15% SDS-PAGE. D, purified recombinant PhLPL (400 nM) was phosphorylated by CK2 (0.3 milliunit) in the absence or presence of 30 µM heparin at 37 °C for 120 min. SDS-PAGE was performed on 15% gel and subjected to phosphorimaging. Phosphorylation of recombinant PhLPL by CK2 caused a gel mobility shift similar to that seen in native tissue.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

G-protein function is regulated by different classes of proteins, most notably the RGS proteins and the members of the phosducin family. The members of the phosducin family bind to the Gbeta gamma -subunits (30, 31) and therefore inhibit G-protein function. This might result in the disruption of the G-protein cycle, (32, 33) and/or in the inhibition of Gbeta gamma -mediated effects like activation of PLCbeta isoforms and G-protein-coupled receptor kinase 2 (9, 34, 35). In this work, we used the activation of a Gbeta gamma -dependent phospholipase Cbeta 2 in HEK 293 cells as a functional readout of Gbeta gamma -inhibition to demonstrate that PhLP inhibits Gbeta gamma -functions in living cells. According to present knowledge, PhLP exists in two isoforms: 1) the long variant PhLPL with an additional N terminus of 83 amino acids and 2) the short variant PhLPS, which lacks this N terminus (Figs. 5A and 8) (1). However, the functional differences of these two isotypes in living cells remained to be elucidated, because (a) in vitro experiments showed that the short form, which lacks one Gbeta gamma -binding region according to structural data (Fig. 8) (31), exhibited a markedly reduced binding affinity toward Gbeta gamma -subunits compared with PhLPL and phosducin (2, 5) and (b) tissue levels of the PhLP isoforms appropriate for a physiological role in Gbeta gamma -inhibition could only be demonstrated for the long form, PhLPL (4, 5). This finding appeared to suggest that the physiological Gbeta gamma -regulator should be the long form, PhLPL. Our present data show that in contrast to this hypothesis, PhLPS is an effective regulator of Gbeta gamma -function in HEK 293 cells. The yeast phosducin homolog resembles PhLPS in size and domain structure (Fig. 8), suggesting that important Gbeta gamma -regulating properties are contained in these proteins. Furthermore, our data suggest that the different forms of PhLP cooperate in inhibiting Gbeta gamma to a variable extent in that the phosphorylated form of PhLPL appears to have a partial dominant negative effect on the inhibitory function of PhLPS.


View larger version (8K):
[in this window]
[in a new window]
 
Fig. 8.   Topology model of phosducin, PhLPL and PhLPS and the yeast phosducin homolog derived from the crystal structure of phosducin (31). Shown are the phosducin structural domains. The N terminus consists of three alpha -helices with Gbeta gamma -binding regions and large unresolved areas. The C terminus is a thioredoxin domain consisting of five beta -sheets and three flanking alpha -helices (not marked) with Gbeta gamma -binding regions. PhLPL has all five homologous Gbeta gamma -contact regions, and PhLPS bears four of the five Gbeta gamma -contact regions and resembles the yeast phosducin homolog, which also does not contain the first alpha -helix and first Gbeta gamma -binding region. As in phosducin, the PhLPL N terminus is subject to regulation by phosphorylation (a), most probably by CK2, and this seems to play an important role in vivo. A further possibility for a more long term activation of PhLP would be alternative splicing to the short variant PhLPS (b), which lacks the possibility of N-terminal regulation by phosphorylation and seems to be relevant in the adrenal gland. In primitive eukaryotic organisms such as yeast, the "short phosducin" might be a sufficient principle of Gbeta gamma -regulation.

PhLPS was found in mouse adrenal gland in amounts comparable with the levels of PhLPL in mouse brain and heart. In the latter organs, tissue levels of PhLPL have been calculated to be sufficient for in vivo regulation of G-proteins (5). The detection of PhLPS in adrenal glands is in line with its purification from bovine chromaffin cells (6). These findings underline the contention that not only PhLPL but also PhLPS is a relevant physiological regulator of G-protein function.

In the case of phosducin, it has been shown that G-protein inhibition is subject to regulation by phosphorylation by several kinases, most notably PKA (7, 8, 10, 11). A PKA consensus motif is also present in PhLP (amino acids 117-121 in PhLPL: GKMT*L)2 but does not appear to serve as a PKA site in vitro or in vivo. However, in HEK 293 cells as well as in mouse organs, PhLPL is apparently constitutively phosphorylated in its N terminus at Ser-18, Thr-19, and Ser-20. CK2 is an ubiquitously expressed and constitutively active serine-threonine kinase (12, 13), which has recently been found to constitutively phosphorylate arrestin-3, another protein of the G-protein-coupled receptor signaling pathway (36). Here, we report that recombinant PhLPL but not PhLPS or phosducin were substrates of CK2 phosphorylation, whereas PKA phosphorylated only phosducin. Therefore, we conclude that the different members of the phosducin family are differentially regulated by different kinases. Further evidence that CK2 is a regulatory kinase for PhLPL comes from the findings that (a) Ser-18, Thr-19, and Ser-20 contain the consensus motif for CK2, (b) mutation of the consensus sites into alanines resulted in a non-phosphorylated form in intact cells, (c) progressive N-terminal truncation or serine/threonine to alanine mutation at these sites both converted PhLPL into a protein with the same potency and efficacy as PhLPS, and (d) phosphorylation of PhLPL by kinase activity from HEK cell lysates was inhibited by two different CK2-specific inhibitors, whereas other kinase inhibitors did not result in inhibition.

Taken together, these findings indicate a regulatory function of the N terminus of PhLPL and underline the role of N-terminal regulation of the members of the phosducin family. Our data also show that PhLP isoforms differ in the mode of activity control and that the Gbeta gamma -inhibitory effects of PhLPL are subject to regulation via the N-terminal domain. Phosphorylation of the N terminus, in vivo most probably by CK2, diminishes the ability of PhLPL to inhibit Gbeta gamma -functions. The analysis of PhLP expression in mouse organs shows that both mechanisms are used in vivo.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed. Tel.: 49-931-20148400; Fax: 49-931-20148539; E-mail: lohse@toxi.uni-wuerzburg.de.

Published, JBC Papers in Press, December 3, 2002, DOI 10.1074/jbc.M206347200

2 Asterisk in sequence denotes potential phosphorylation site.

    ABBREVIATIONS

The abbreviations used are: PhLP, phosducin-like protein; PhLPL, long form of PhLP; PhLPS, short form of PhLP; Gbeta gamma , G-protein beta gamma -subunit; PKA, cAMP-dependent protein kinase; GRK2, G-protein-coupled receptor kinase 2; HEK, human embryonic kidney; BAPTA-AM, 1,2-bis(O-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetra(acetoxymethy)ester; DRB, 5,6-dichloro-1-beta -D-ribofuranylbenzimidazole; CK2, casein kinase 2; CT, C terminus; ANOVA, analysis of variance; lambda -PPase, lambda -protein phosphatase; PLC, phospholipase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Miles, M. F., Barhite, S., Sganga, M., and Elliott, M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10831-10835[Abstract]
2. Schröder, S., and Lohse, M. J. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 2100-2104[Abstract/Free Full Text]
3. Thibault, C., Sganga, M. W., and Miles, M. F. (1997) J. Biol. Chem. 272, 12253-12256[Abstract/Free Full Text]
4. Thibault, C., Feng Wang, J., Charnas, R., Mirel, D., Barhite, S., and Miles, M. F. (1999) Biochim. Biophys. Acta 1444, 346-354[Medline] [Order article via Infotrieve]
5. Schröder, S., and Lohse, M. J. (2000) Naunyn-Schmiedeberg's Arch. Pharmacol. 362, 435-439[CrossRef][Medline] [Order article via Infotrieve]
6. Gensse, M., Vitale, N., Chasserot-Golaz, S., and Bader, M. F. (2000) FEBS Lett. 480, 184-188[CrossRef][Medline] [Order article via Infotrieve]
7. Lee, R. H., Brown, B. M., and Lolley, R. N. (1990) J. Biol. Chem. 265, 15860-15866[Abstract/Free Full Text]
8. Bauer, P. H., Müller, S., Puzicha, M., Pippig, S., Obermaier, B., Helmreich, E. J., and Lohse, M. J. (1992) Nature 358, 73-76[CrossRef][Medline] [Order article via Infotrieve]
9. Yoshida, T., Willardson, B. M., Wilkins, J. F., Jensen, G. J., Thornton, B. D., and Bitensky, M. W. (1994) J. Biol. Chem. 269, 24050-24057[Abstract/Free Full Text]
10. Ruiz-Gomez, A., Humrich, J., Murga, C., Quitterer, U., Lohse, M. J., and Mayor, F., Jr. (2000) J. Biol. Chem. 275, 29724-29730[Abstract/Free Full Text]
11. Thulin, C. D., Savage, J. R., McLaughlin, J. N., Truscott, S. M., Old, W. M., Ahn, N. G., Resing, K. A., Hamm, H. E., Bitensky, M. W., and Willardson, B. M. (2001) J. Biol. Chem. 276, 23805-23815[Abstract/Free Full Text]
12. Allende, J. E., and Allende, C. C. (1995) FASEB J. 9, 313-323[Abstract/Free Full Text]
13. Pinna, L. A., and Meggio, F. (1997) Prog. Cell Cycle Res. 3, 77-97[Medline] [Order article via Infotrieve]
14. Liu, F. T., Zinnecker, M., Hamaoka, T., and Katz, D. H. (1979) Biochemistry 18, 690-693[Medline] [Order article via Infotrieve]
15. Green, N., Alexander, H., Olson, A., Alexander, S., Shinnick, T. M., Sutcliffe, J. G., and Lerner, R. A. (1982) Cell 28, 477-487[Medline] [Order article via Infotrieve]
16. Cullen, B. R. (1987) Methods Enzymol. 152, 684-704[Medline] [Order article via Infotrieve]
17. Quitterer, U., AbdAlla, S., Jarnagin, K., and Müller-Esterl, W. (1996) Biochemistry 35, 13368-13377[CrossRef][Medline] [Order article via Infotrieve]
18. Malecz, N., Bambino, T., Bencsik, M., and Nissenson, R. A. (1998) Mol. Endocrinol. 12, 1846-1856[Abstract/Free Full Text]
19. Xu, J., Wu, D., Slepak, V. Z., and Simon, M. I. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 2086-2090[Abstract]
20. Quitterer, U., and Lohse, M. J. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 10626-10631[Abstract/Free Full Text]
21. Dicker, F., Quitterer, U., Winstel, R., Honold, K., and Lohse, M. J. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 5476-5481[Abstract/Free Full Text]
22. Ruegg, U. T., and Burgess, G. M. (1989) Trends Pharmacol. Sci. 10, 218-220[CrossRef][Medline] [Order article via Infotrieve]
23. Billman, G. E. (1993) Am. J. Physiol. 265, H1529-H1535[Abstract/Free Full Text]
24. Jiang, S., Chow, S. C., Nicotera, P., and Orrenius, S. (1994) Exp. Cell Res. 212, 84-92[CrossRef][Medline] [Order article via Infotrieve]
25. Block, K., Boyer, T. G., and Yew, P. R. (2001) J. Biol. Chem. 276, 41049-41058[Abstract/Free Full Text]
26. Zandomeni, R. O. (1989) Biochem. J. 262, 469-473[Medline] [Order article via Infotrieve]
27. Kim, S. J., and Kahn, C. R. (1997) Biochem. Biophys. Res. Commun. 234, 681-685[CrossRef][Medline] [Order article via Infotrieve]
28. Lin, A., Frost, J., Deng, T., Smeal, T., al-Alawi, N., Kikkawa, U., Hunter, T., Brenner, D., and Karin, M. (1992) Cell 70, 777-789[Medline] [Order article via Infotrieve]
29. Zhuo, S., Clemens, J. C., Hakes, D. J., Barford, D., and Dixon, J. E. (1993) J. Biol. Chem. 268, 17754-17761[Abstract/Free Full Text]
30. Lee, R. H., Lieberman, B. S., and Lolley, R. N. (1987) Biochemistry 26, 3983-3990[Medline] [Order article via Infotrieve]
31. Gaudet, R., Bohm, A., and Sigler, P. B. (1996) Cell 87, 577-588[Medline] [Order article via Infotrieve]
32. Müller, S., Straub, A., Schröder, S., Bauer, P. H., and Lohse, M. J. (1996) J. Biol. Chem. 271, 11781-11786[Abstract/Free Full Text]
33. Bauer, P. H., and Lohse, M. J. (1998) Naunyn-Schmiedeberg's Arch. Pharmacol. 357, 371-377[Medline] [Order article via Infotrieve]
34. Hekman, M., Bauer, P. H., Söhlemann, P., and Lohse, M. J. (1994) FEBS Lett. 343, 120-124[CrossRef][Medline] [Order article via Infotrieve]
35. Schulz, K., Danner, S., Bauer, P., Schröder, S., and Lohse, M. J. (1996) J. Biol. Chem. 271, 22546-22551[Abstract/Free Full Text]
36. Kim, Y. M., Barak, L. S., Caron, M. G., and Benovic, J. L. (2002) J. Biol. Chem. 277, 16837-16846[Abstract/Free Full Text]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.